IBCM Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
IBCM Pharma
Largest movements
- Cash +€9,819
up €9,819 (+208907.7%), from €5 to €9,823
mainly Net result for the year (+€21,109) and Tax, wage and social debts (+€2,537)
- Receivables within one year +€8,884
up €8,884 (+10.9%), from €81,676 to €90,560
of which Other amounts receivable: +€17,671
- Profit (loss) carried forward +€21,109
up €21,109 (+37.0%), from €57,000 to €78,108
- Trade debts -€4,574
down €4,574 (-83.6%), from €5,470 to €896
- Tax, wage and social debts +€2,537
up €2,537 (+13.9%), from €18,289 to €20,826
- Gross operating margin +€906
up €906 (+3.3%), from €27,650 to €28,556
- Staff costs +€832
new in 2025: €832
- Taxes +€500
up €500 (+8.4%), from €5,961 to €6,461
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €81,758 | €100,830 | +€19,072 | +23.3% |
| Current assets | 29/58 | €81,758 | €100,830 | +€19,072 | +23.3% |
| Amounts receivable within one year | 40/41 | €81,676 | €90,560 | +€8,884 | +10.9% |
| Trade receivables | 40 | €8,788 | - | -€8,788 | |
| Other amounts receivable | 41 | €72,888 | €90,560 | +€17,671 | +24.2% |
| Cash at bank and in hand | 54/58 | €5 | €9,823 | +€9,819 | +208907.7% |
| Deferred charges and accrued income | 490/1 | €78 | €447 | +€369 | +476.4% |
| Total equity and liabilities | 10/49 | €81,758 | €100,830 | +€19,072 | +23.3% |
| Equity | 10/15 | €58,000 | €79,108 | +€21,109 | +36.4% |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Outside capital | 11 | €1,000 | €1,000 | = | 0.0% |
| Other | 1109/19 | €1,000 | €1,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €57,000 | €78,108 | +€21,109 | +37.0% |
| Amounts payable | 17/49 | €23,758 | €21,721 | -€2,037 | -8.6% |
| Amounts payable within one year | 42/48 | €23,758 | €21,721 | -€2,037 | -8.6% |
| Trade debts | 44 | €5,470 | €896 | -€4,574 | -83.6% |
| Suppliers | 440/4 | €5,470 | €896 | -€4,574 | -83.6% |
| Taxes, remuneration and social security | 45 | €18,289 | €20,826 | +€2,537 | +13.9% |
| Taxes | 450/3 | €18,289 | €20,826 | +€2,537 | +13.9% |
| Non-recurring operating income | 76A | - | €4,611 | +€4,611 | |
| Remuneration, social security and pensions | 62 | - | €832 | +€832 | |
| Gross operating margin | 9900 | €27,650 | €28,556 | +€906 | +3.3% |
| Operating profit (loss) | 9901 | €27,650 | €27,724 | +€74 | +0.3% |
| Financial charges | 65/66B | €89 | €155 | +€66 | +74.4% |
| Recurring financial charges | 65 | €89 | €155 | +€66 | +74.4% |
| Profit (loss) for the period before taxes | 9903 | €27,561 | €27,569 | +€8 | 0.0% |
| Income taxes | 67/77 | €5,961 | €6,461 | +€500 | +8.4% |
| Profit (loss) for the period | 9904 | €21,601 | €21,109 | -€492 | -2.3% |
| Profit (loss) for the period to be appropriated | 9905 | €21,601 | €21,109 | -€492 | -2.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.